Neuroreceptor changes in Alzheimer disease.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Cerebrovascular and brain metabolism reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 1486017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Muscarinic receptor compensation in hippocampus of Alzheimer patients

  2005cited by this paper
• Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile

  2005cited by this paper
• Brain dopamine D-2 receptors in senile dementia

  2005cited by this paper
• Loss of cortical GABA uptake sites in Alzheimer's disease

  2005cited by this paper
• Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment

  2004cited by this paper
• In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography.

  1992cited by this paper
• Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?

  1992cited by this paper
• Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia

  1992cited by this paper
• Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease.

  1992cited by this paper
• Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report).

  1992cited by this paper
• Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases

  1992cited by this paper
• Adenylyl Cyclase Activity in Postmortem Human Brain: Evidence of Altered G Protein Mediation in Alzheimer's Disease

  1992cited by this paper
• Coupling of human brain cerebral cortical alpha 2-adrenoceptors to GTP-binding proteins in Alzheimer's disease.

  1991cited by this paper
• Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes.

  1991cited by this paper
• Terminal coma affects messenger RNA detection in post mortem human temporal cortex.

  1991cited by this paper
• Coupling of ml Muscarinic Receptors to G Protein in Alzheimer Disease

  1991cited by this paper
• Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies

  1991cited by this paper
• A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex

  1991cited by this paper
• Somatostatin receptors and the modulation of adenylyl cyclase activity in Alzheimer's disease.

  1991cited by this paper
• Prevalence of Alzheimer's disease and other dementias in an elderly urban population

  1991cited by this paper
• A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease.

  1991cited by this paper
• An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

  1991cited by this paper
• Platelet [3H]paroxetine binding to 5-HT uptake sites in Alzheimer's disease.

  1991cited by this paper
• Changes of muscarinic cholinergic binding by lymphocytes in parkinson's disease with and without dementia

  1991cited by this paper
• Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

  1991cited by this paper
• Interleukin‐2 receptor in peripheral blood lymphocytes of Alzheimer's disease patients

  1991cited by this paper
• PET: A biological imaging technique

  1991cited by this paper
• Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain.

  1991cited by this paper
• Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease.

  1991cited by this paper
• Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease.

  1991cited by this paper
• Alzheimer's disease: specific increases in a G protein subunit (Gs alpha) mRNA in hippocampal and cortical neurons.

  1991cited by this paper
• An analysis of lymphocyte 3H-N-methyl-scopolamine binding in neurological patients. Evidence of altered binding in Alzheimer's disease.

  1991cited by this paper
• Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review.

  1991cited by this paper
• Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease

  1990cited by this paper
• Neuropeptide Y receptor binding sites in human brain. Possible alteration in Alzheimer's disease.

  1990cited by this paper
• Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

  1990cited by this paper
• Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia.

  1990cited by this paper
• Decreased uptake and binding of11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography

  1990cited by this paper
• Neurochemical aspects on aging and diseases with cognitive impairment

  1990cited by this paper
• Glutamatergic neurotransmission in Alzheimer's disease.

  1990cited by this paper
• Alzheimer's disease: Changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors—an autoradiographic study

  1990cited by this paper
• Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapy

  1990cited by this paper
• Age‐related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET)

  1990cited by this paper
• Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types

  1990cited by this paper
• Cholinergic receptors in human brain: Effects of aging and alzheimer disease

  1990cited by this paper
• Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.

  1990cited by this paper
• Neuropeptides and Alzheimer's Disease

  1990cited by this paper
• Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease.

  1990cited by this paper
• Nicotinic binding sites in cerebral cortex and hippocampus in alzheimer's dementia

  1989cited by this paper
• Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease.

  1989cited by this paper
• Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.

  1989cited by this paper
• [3H]N-methylscopolamine binding to muscarinic receptors in human peripheral blood lymphocytes: characterization, localization on T-lymphocyte subsets and age-dependent changes.

  1989cited by this paper
• Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer's disease.

  1989cited by this paper
• Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease.

  1988cited by this paper
• Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains.

  1988cited by this paper
• Muscarinic receptor differentiation.

  1988cited by this paper
• VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by Alzheimer's disease/senile dementia of the Alzheimer type.

  1988cited by this paper
• Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease

  1988cited by this paper
• Distribution of nicotinic cholinergic receptors in the rat tel- and diencephalon: a quantitative receptor autoradiographical study using [3H]-acetylcholine, [alpha-125I]bungarotoxin and [3H]nicotine.

  1988cited by this paper
• Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains.

  1988cited by this paper
• Muscarinic Cholinergic Receptor Subtypes in Hippocampus in Human Cognitive Disorders

  1988cited by this paper
• Differential Alteration of Various Cholinergic Markers in Cortical and Subcortical Regions of Human Brain in Alzheimer's Disease

  1988cited by this paper
• Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.

  1988cited by this paper
• Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease.

  1988cited by this paper
• Topographical distribution of neurochemical changes in Alzheimer's disease.

  1988cited by this paper
• Galanin‐Like Immunoreactivity Is Unchanged in Alzheimer's Disease and Parkinson's Disease Dementia Cerebral Cortex

  1988cited by this paper
• [3H]TCP binding sites in Alzheimer's disease.

  1987cited by this paper
• Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia.

  1987cited by this paper
• Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease.

  1987cited by this paper
• Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia.

  1987cited by this paper
• Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases.

  1987cited by this paper
• 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders.

  1987cited by this paper
• Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding

  1987cited by this paper
• Identification of a family of muscarinic acetylcholine receptor genes.

  1987cited by this paper
• Loss of hippocampal [3H]TCP binding in Alzheimer's disease.

  1987cited by this paper
• Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease

  1987cited by this paper
• Guanine nucleotide modulation of muscarinic cholinergic receptor binding in postmortem human brain--a preliminary study in Alzheimer's disease.

  1987cited by this paper
• Dopamine and Serotonin Systems in Human and Rodent Brain: Effects of Age and Neurodegenerative Disease

  1987cited by this paper
• A disorder of cortical GABAergic innervation in Alzheimer's disease.

  1987cited by this paper
• Cortical GABAB and GABAA receptors in Alzheimer's disease

  1987cited by this paper
• Glutamate deficits in Alzheimer's disease

  1987cited by this paper
• Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex.

  1987cited by this paper
• Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains.

  1986cited by this paper
• Binding of the Novel Serotonin Agonist 8‐Hydroxy‐2‐(Di‐n‐Propylamino) Tetralin in Normal and Alzheimer Brain

  1986cited by this paper
• Alzheimer's disease: a correlative study.

  1986cited by this paper
• Characterization of l‐[3H]Nicotine Binding in Human Cerebral Cortex: Comparison Between Alzheimer's Disease and the Normal

  1986cited by this paper
• Antemortem markers of Alzheimer's disease.

  1986cited by this paper
• Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease

  1986cited by this paper
• Nicotinic acetylcholine binding sites in Alzheimer's disease.

  1986cited by this paper
• The cholinergic hypothesis--ten years on.

  1986cited by this paper
• Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.

  1986cited by this paper
• Density and distribution of NMDA receptors in the human hippocampus in Alzheimer's disease.

  1986cited by this paper
• Extraneural cholinergic markers in Alzheimer's and Parkinson's disease.

  1986cited by this paper
• Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease.

  1986cited by this paper
• Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia.

  1986cited by this paper
• Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer‐Type Dementia

  1986cited by this paper
• Brain muscarinic receptors in senile dementia.

  1985cited by this paper
• Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.

  1985cited by this paper
• Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases.

  1985cited by this paper
• Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation.

  1985cited by this paper

• Evaluation of the Alterations in Central Cholinergic Neurotransmission in Aging and Amyloid Precursor Protein Knock‐In Mice

  2025cites this paper
• Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions

  2023cites this paper
• Daily Energy Intake Distribution and Cognitive Performance in Non-Demented Individuals

  2023cites this paper
• PET image harmonization using smoothing-CycleGAN

  2022cites this paper
• Computational investigation of mechanistic insights of Aβ42 interactions against extracellular domain of nAChRα7 in Alzheimer’s disease

  2019cites this paper
• A systematic review on donepezil-based derivatives as potential cholinesterase inhibitors for Alzheimer's disease.

  2018cites this paper
• The Role of Human α7-Nicotinic Acetylcholine Receptors in Mediating Neuroprotective Action of Curcumin

  2018cites this paper
• Neuroprotective Effects of Neuropeptide Y and Y2 and Y5 Receptor Agonists In Vitro and In Vivo

  2017cites this paper
• THE LIMBIC - HYPOTHALAMIC - PITUITARY - ADRENAL AXIS IN ALZHEIMER’S DISEASE

  2017cites this paper
• Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?

  2017cites this paper
• A Novel Form of Compensation in the Tg2576 Amyloid Mouse Model of Alzheimer’s Disease

  2016cites this paper
• Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer’s Disease

  2016cites this paper
• Non-neuronal cholinergic system in regulation of immune function with a focus on α7 nAChRs.

  2015cites this paper
• Serotonin In Brain: A Cue forAlzheimer’s Disease

  2014cites this paper
• Neural nAChRs PET imaging probes

  2014cites this paper
• p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells.

  2014cites this paper
• Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease

  2014cites this paper
• p 53 Functional Inhibitors Behaving Like Pi fi thrin ‐ β Counteract the Alzheimer Peptide Non-β-amyloid Component E ff ects in Human SH-SY 5 Y Cells

  2014cites this paper
• Serotonergic fibers distribution in the midline and intralaminar thalamic nuclei in the rock cavy (Kerodon rupestris).

  2014cites this paper
• Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

  2014cites this paper
• Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

  2013cites this paper
• Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.

  2013cites this paper
• Structural and functional cortical disconnection in Alzheimer's disease: a combined study using diffusion tensor imaging and transcranial magnetic stimulation.

  2013cites this paper
• The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited.

  2012cites this paper
• Ligand-gated ion channels: new insights into neurological disorders and ligand recognition.

  2012cites this paper
• AGE DEPENDENT ΒETA-AMYLOID ISOFORMS AND IMPLICATIONS OF DIFFERENT DRUG TREATMENTS AS STUDIED IN DIFFERENT TRANSGENIC MOUSE MODELS AND CELL LINES

  2012cites this paper
• Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer's disease.

  2012cites this paper
• Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

  2012cites this paper
• Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders

  2011cites this paper
• The relationship between motor cortex excitability and severity of Alzheimer's disease: a transcranial magnetic stimulation study.

  2011cites this paper
• The cholinergic system in aging and neuronal degeneration.

  2011cites this paper
• Study of new propargylamine and donepezil-derived compounds as multitarget agents for the treatment of alzheimer’s disease

  2011cites this paper
• Transcranial magnetic stimulation in Alzheimer’s disease: a neurophysiological marker of cortical hyperexcitability

  2011cites this paper
• The effects of nerve growth factor the neuropeptide Y contente of nucleus accumbens of old rats: stereological study

  2011cites this paper
• The use of PET in Alzheimer disease

  2010cites this paper
• Behavioural phenotype of APPC100.V717F transgenic mice over-expressing a mutant Abeta-bearing fragment is associated with reduced NMDA receptor density.

  2010cites this paper
• eview he cholinergic system in aging and neuronal degeneration

  2010cites this paper
• Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of α7 nicotinic receptors and internalization of NMDA receptors

  2010cites this paper
• The effects of nerve growth factor upon the neuropeptide Y content of nucleus accumbens of old rats : a stereological study

  2010cites this paper
• Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo.

  2009cites this paper
• Nicotinic acetylcholine receptors: an overview on drug discovery

  2009cites this paper
• Neuroprotection in alzheimer’s disease — new strategies for treatment

  2009cites this paper
• Neuroprotective and Neurotoxic Effects of Nicotine

  2009cites this paper
• Identifikation und funktionelle Charakterisierung genetischer Risikofaktoren der Alzheimer Krankheit

  2009cites this paper
• Molecular imaging in dementia

  2008cites this paper
• Division of Alzheimer Neurobiology, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden STEM CELL DIFFERENTIATION, PLASTICITY AND REGENERATIVE MECHANISMS IN THE CHOLINERGIC SYSTEM – IMPLICATIONS FOR ALZHEIMER ́S DISEASE

  2008cites this paper
• In Vivo Imaging of Neurotransmission and Brain Receptors in Dementia

  2008cites this paper
• Developmental Neurotoxicity in Mice Neonatally Co-exposed to Environmental Agents : PCB, PBDE, Methyl Mercury and Ionized Radiation - Interactions and Effects

  2008cites this paper
• Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

  2008cites this paper
• Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study.

  2008cites this paper
• Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment

  2008cites this paper
• Selective immunolesion of cholinergic neurons leads to long-term changes in 5-HT2A receptor levels in hippocampus and frontal cortex.

  2007cites this paper
• Effects of wild-type and mutant human amyloid precursor protein on cortical afferent network

  2007cites this paper
• A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease.

  2007cites this paper
• In Vitro Imaging Techniques in Neurodegenerative Diseases

  2007cites this paper
• The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease

  2006cites this paper
• Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease

  2006cites this paper
• Ion channel diseases of the central nervous system.

  2006cites this paper
• Interactive Mechanism Between β-Amyloid Process , α 7 Nicotinic Receptor , Glial Cell Activation and Oxidative Stress in Alzheimer ' s Disease

  2006cites this paper
• Interactive mechanism between beta-amyloid process, alfa7 nicotinic receptor, glial cell activation and oxidative stress in Alzheimer's disease

  2006cites this paper
• Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer‐like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein

  2006cites this paper
• Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.

  2006cites this paper
• Plasma levels of neuropeptides in Alzheimer's disease

  2006cites this paper
• Toxicity mediated by soluble oligomers of β‐amyloid(1–42) on cholinergic SN56.B5.G4 cells

  2006cites this paper
• Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice

  2006cites this paper
• Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.

  2006cites this paper
• Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology.

  2006cites this paper
• Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration

  2005influential citation
• Neuro-modulation, aminergic neuro-disinhibition and neuro-degeneration. Draft of a comprehensive theory for Alzheimer disease.

  2005cites this paper
• Interactions between Neuronal Nicotinic Acetylcholine Receptors, N-Methyl-D-Aspartate Receptors and β-amyloid in the Brain of Genetically Modified Mice

  2005cites this paper
• On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease.

  2005cites this paper
• Participation in Novelty-Seeking Leisure Activities and Alzheimer’s Disease

  2005cites this paper
• Basal Forebrain Cholinergic Lesion by 192 IgG-Saporin

  2005cites this paper
• Early changes in Aβ levels in the brain of APPswe transgenic mice—Implication on synaptic density, α7 neuronal nicotinic acetylcholine- and N-methyl-d-aspartate receptor levels

  2005cites this paper
• Interactions between neuronal nicotinic acetylcholine receptors, N-Methyl-Aspartate receptors and beta-amyloid in the brain of genetically modified mice : Implications for Alheimer´s disease

  2005cites this paper
• Basal Forebrain Cholinergic Dysfunction in Alzheimer’s Disease – Interrelationship with β-amyloid, Inflammation and Neurotrophin Signaling

  2005cites this paper
• Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.

  2005cites this paper
• Beta-Amyloid₁₋₄₂- induced intracellular signaling pathways, functional responses and modulation by 4-aminopyridine in microglia

  2005cites this paper
• PET imaging of amyloid in Alzheimer's disease.

  2004cites this paper
• A water extract of Curcuma longa L. (Zingiberaceae) rescues PC12 cell death caused by pyrogallol or hypoxia/reoxygenation and attenuates hydrogen peroxide induced injury in PC12 cells.

  2004cites this paper
• Differential Changes From Selected Brain Immunolesion of the Forebrain System in Cholinergic Markers Regions After Specific Rat Cholinergic Basal

  2004cites this paper
• Attenuating effect of a traditional korean formulation, Paeng‐Jo‐Yeon‐Nyeon‐Baek‐Ja‐In‐Hwan (PJBH), on hydrogen peroxide‐induced injury in PC12 cells

  2004cites this paper
• Dementia and Cerebrovascular Disease

  2004cites this paper
• Neuronal nicotinic receptors: from structure to pathology.

  2004cites this paper
• Awater extract of Curcuma longa L . ( Zingiberaceae ) rescues PC 12 cell death caused by pyrogallol or hypoxia / reoxygenation and attenuates hydrogen peroxide induced injury in PC 12 cells

  2004cites this paper
• New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.

  2004cites this paper
• Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients.

  2004cites this paper
• The identification and characterization of excitotoxic nerve-endings in Alzheimer disease.

  2004cites this paper
• Patients with Alzheimer’s Disease May Be Particularly Susceptible to Adverse Effects of Statins

  2004cites this paper
• Impairment of Gsα function in human brain cortex of Alzheimer’s disease: comparison with normal aging

  2004cites this paper
• Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients

  2004cites this paper
• Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease

  2003cites this paper
• Novel SPECT Receptor Ligands for the Investigation of Dementia

  2003cites this paper
• parvalbumin-containing neurons in the rat brain

  2003cites this paper
• Alterations in cholinergic and non‐cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with β‐amyloid plaque pathology

  2003influential citation
• Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings.

  2003cites this paper
• Role and distribution of serotonin type 2A receptors in Alzheimer’s disease

  2003cites this paper
• Motor cortex excitability in Alzheimer's disease: A transcranial magnetic stimulation study

  2003cites this paper
• Toward an Early Diagnosis and Treatment of Alzheimer's Disease

  2003cites this paper
• Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function.

  2003cites this paper